Free Trial
→ My prediction for December 8th (From Behind the Markets) (Ad)tc pixel
NASDAQ:INKT

MiNK Therapeutics Q3 2026 Earnings Date & Estimates

MiNK Therapeutics logo
$10.48 +0.13 (+1.21%)
Closing price 11/6/2026 03:59 PM Eastern
Extended Trading
$10.88 +0.40 (+3.84%)
As of 05:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MiNK Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MiNK Therapeutics in Q3 2026

MiNK Therapeutics is expected to post earnings of -$0.66 per share on revenue of $75 thousand. In the same quarter a year earlier MiNK Therapeutics reported -$0.65 per share. MiNK Therapeutics last reported on August 13, 2026, posting -$0.62 per share and missing the -$0.60 consensus estimate. MiNK Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.66
Expected Revenue
$75 thousand
Prior-Year EPS
-$0.65

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.62 (Missed by -$0.02)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

MiNK Therapeutics Q3 2026 Earnings FAQ

MiNK Therapeutics (NASDAQ:INKT) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

MiNK Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MiNK Therapeutics to post earnings of -$0.66 per share for Q3 2026.

The consensus revenue estimate for MiNK Therapeutics is $75 thousand for Q3 2026.

MiNK Therapeutics Earnings Headlines

Analysts Issue Forecasts for INKT Q3 Earnings
November 8 at 1:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31184828
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer ...
November 6 at 11:29 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/mink-therapeutics-new-data-highlights-its-off-the-shelf-inkt-cell-therapy-targets-two-key-mechanisms-of-tumor-resistance-presented-at-the-society-of-immunotherapy-of-cancer-sitc-2026-1036729917
One Ticker Tied to a Coming 401k Change
An email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.tc pixel
 |  Brownstone Research (Ad)
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
November 6 at 9:48 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/06/3397617/0/en/mink-therapeutics-new-data-highlights-its-off-the-shelf-inkt-cell-therapy-targets-two-key-mechanisms-of-tumor-resistance-presented-at-the-society-of-immunotherapy-of-cancer-sitc-20.html
MiNK Therapeutics (NASDAQ:INKT) Now Covered by Analysts at HC Wainwright
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180149
MiNK Therapeutics (INKT) Set to Post Quarterly Earnings on Wednesday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179289
See More MiNK Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MiNK Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiNK Therapeutics and other key companies, straight to your email.

About MiNK Therapeutics

MiNK Therapeutics (NASDAQ:INKT) is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors. The company’s research and development efforts are focused primarily on solid tumors and other difficult-to-treat cancers.

MiNK Therapeutics was established to advance iNKT-based cellular immunotherapies and conducts its development activities through preclinical research and clinical studies. The company is headquartered in the United States and is listed on the Nasdaq under the symbol INKT. Information about specific commercial operations and marketed products is limited because MiNK remains focused on research and clinical development.

View MiNK Therapeutics Profile
Earnings Tools